27457539|t|Safety and immunogenecity of a live attenuated Rift Valley fever vaccine (CL13T) in camels
27457539|a|Rift Valley fever is an emerging zoonotic viral disease, enzootic and endemic in Africa and the Arabian Peninsula, which poses a significant threat to both human and animal health. The disease is most severe in ruminants causing abortions in pregnant animals, especially sheep animals and high mortality in young populations. High mortality rates and severe clinical manifestation have also been reported among camel populations in Africa, to attend however none of the currently available live vaccines against RVF have been tested for safety and efficacy in this species. In this study, the safety and efficacy (through a neutralizing antibody response) of the thermostable live attenuated RVF CL13T vaccine were evaluated in camels in two different preliminary experiments involving 16 camels, (that 12 camels and 4 pregnant camels). The study revealed that the CL13T vaccine was safe to use in camels and no abortions or teratogenic effects were observed. The single dose of the vaccine stimulated a strong and long-lasting neutralizing antibody response for up to 12 months. The presence of neutralization antibodies is likely to correlate with protection; however protection would need to be confirmed by challenge experiments using the virulent RVF virus.
27457539	0	6	Safety	T068	C0036043
27457539	11	25	immunogenecity	T062	C4054739
27457539	36	46	attenuated	T121,T129	C0042211
27457539	47	72	Rift Valley fever vaccine	T121,T129	C1548485
27457539	74	79	CL13T	T121,T129	C1548485
27457539	84	90	camels	T015	C0006801
27457539	91	108	Rift Valley fever	T047	C0035613
27457539	124	132	zoonotic	T001	C1628327
27457539	133	146	viral disease	T047	C0042769
27457539	148	156	enzootic	T047	C0277551
27457539	161	168	endemic	T047	C0277550
27457539	172	178	Africa	T083	C0001737
27457539	187	204	Arabian Peninsula	T083	C0003671
27457539	220	231	significant	T078	C0750502
27457539	232	238	threat	T078	C0749385
27457539	247	252	human	T016	C0086418
27457539	257	263	animal	T008	C0003062
27457539	264	270	health	T047	C3534575
27457539	276	283	disease	T047	C0035613
27457539	292	298	severe	T080	C0205082
27457539	302	311	ruminants	T015	C0035950
27457539	312	319	causing	T169	C0678227
27457539	320	329	abortions	T046	C0149814
27457539	333	341	pregnant	T040	C0032961
27457539	342	349	animals	T008	C0003062
27457539	362	375	sheep animals	T015	C0036945
27457539	385	394	mortality	T081	C0205848
27457539	398	403	young	T079	C0332239
27457539	404	415	populations	T098	C1257890
27457539	422	437	mortality rates	T081	C0205848
27457539	442	448	severe	T080	C0205082
27457539	449	457	clinical	T080	C0205210
27457539	458	471	manifestation	T080	C1280464
27457539	487	495	reported	T170	C0684224
27457539	502	507	camel	T015	C0006801
27457539	508	519	populations	T098	C1257890
27457539	523	529	Africa	T083	C0001737
27457539	561	570	currently	T079	C0521116
27457539	571	580	available	T169	C0470187
27457539	581	594	live vaccines	T121,T129	C0042211
27457539	603	606	RVF	T047	C0035613
27457539	617	623	tested	T169	C0039593
27457539	628	634	safety	T068	C0036043
27457539	639	647	efficacy	T080	C1280519
27457539	656	663	species	T185	C1705920
27457539	673	678	study	T062	C2603343
27457539	684	690	safety	T068	C0036043
27457539	695	703	efficacy	T080	C1280519
27457539	715	736	neutralizing antibody	T116,T129	C0475463
27457539	737	745	response	T032	C0871261
27457539	754	782	thermostable live attenuated	T121,T129	C0042211
27457539	783	800	RVF CL13T vaccine	T121,T129	C1548485
27457539	806	815	evaluated	T058	C0220825
27457539	819	825	camels	T015	C0006801
27457539	833	842	different	T080	C1705242
27457539	843	854	preliminary	T079	C0439611
27457539	855	866	experiments	T062	C0681814
27457539	880	886	camels	T015	C0006801
27457539	897	903	camels	T015	C0006801
27457539	910	918	pregnant	T040	C0032961
27457539	919	925	camels	T015	C0006801
27457539	932	937	study	T062	C2603343
27457539	938	946	revealed	T080	C0443289
27457539	956	969	CL13T vaccine	T121,T129	C1548485
27457539	974	978	safe	T068	C0036043
27457539	982	985	use	T169	C0457083
27457539	989	995	camels	T015	C0006801
27457539	1003	1012	abortions	T046	C0149814
27457539	1016	1035	teratogenic effects	T046	C0232910
27457539	1041	1049	observed	T169	C1441672
27457539	1062	1066	dose	T081	C0178602
27457539	1074	1081	vaccine	T121,T129	C0042211
27457539	1095	1101	strong	T080	C0442821
27457539	1119	1140	neutralizing antibody	T116,T129	C0475463
27457539	1141	1149	response	T032	C0871261
27457539	1163	1169	months	T079	C0439231
27457539	1175	1183	presence	T033	C0150312
27457539	1187	1212	neutralization antibodies	T116,T129	C0475463
27457539	1226	1240	correlate with	T080	C0332281
27457539	1241	1251	protection	T033	C1545588
27457539	1261	1271	protection	T033	C1545588
27457539	1289	1301	confirmed by	T080	C0521093
27457539	1312	1323	experiments	T062	C0681814
27457539	1334	1342	virulent	T080	C1520022
27457539	1343	1352	RVF virus	T005	C0035614